The efficient targeting of RUNX2, together with the advances in uncovering the significant molecules/pathways involved in VECs and VICs phenotypic alterations in diabetes, opens new avenues for developing innovative nanotherapeutics for the aortic valve disease in diabetes. This evidence concerns the gene RUNX2 and diabetes mellitus.